Last update 07 Nov 2024
Solifenacin Succinate/Tamsulosin Hydrochloride
Last update 07 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms EC-905, JLP-1207, Vesomni + [1] |
Target |
Mechanism M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists), α1A-AR antagonists(Alpha-1a adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date NL (07 Oct 2013), |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC27H32N2O6 |
InChIKeyRXZMMZZRUPYENV-VROPFNGYSA-N |
CAS Registry242478-38-2 |
View All Structures (2)
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Lower Urinary Tract Symptoms | NL | 07 Oct 2013 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dysuria | Phase 1 | GB | 01 Apr 2010 | |
| Urinary Bladder, Overactive | Phase 1 | GB | 01 Apr 2010 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 1,067 | wlqckkscqj(dbecevxdje) = qhitymclsl vuikvgkusj (ygcpgztxkk, nxozhqaudh - bxkwfvkitm) View more | - | 22 Jan 2016 | |||
Phase 3 | 1,334 | Placebo tamsulosin hydrochloride OCAS 0.4 mg+Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg (Placebo) | dekbmbceaj(lxhfxirjrh) = mznwxfzzir vpmirrqyry (krtjlcwfka, zareqnamwh - xavnwqzqau) View more | - | 17 Dec 2015 | ||
tamsulosin hydrochloride OCAS 0.4 mg+Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg (TOCAS 0.4 mg) | dekbmbceaj(lxhfxirjrh) = cibcqfawvw vpmirrqyry (krtjlcwfka, fcewjibjhq - foxzdfesyr) View more | ||||||
Phase 3 | 1,066 | solifenacin and tamsulosin oral | rduincyxtq(cthtbszjpt) = Urinary retention occurred in 13 of 1208 (1.1%) patients receiving one or more FDCs in NEPTUNE and/or NEPTUNE II; 8 (0.7%) required catheterisation (acute urinary retention [AUR]) iwuljvvcem (gtubhhihju ) | Positive | 01 Feb 2015 | ||
Phase 4 | 70 | (Solifenacin) | bcddtsjqhb(lwafnlggue) = chdahuppgt wwlxxazwsp (mdjotpzqjh, eylveqxdra - wzoiwhgjkp) View more | - | 27 Jan 2015 | ||
(Solifenacin Plus Tamsulosin) | bcddtsjqhb(lwafnlggue) = gskywbikvk wwlxxazwsp (mdjotpzqjh, ydtyvgszwx - rlynakirvy) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free